"Initial clinical response" to neoadjuvant chemotherapy: An in-vivo chemosensitivity test for efficacy in patients with advanced breast cancer

Asian Pacific Journal of Cancer Prevention

Volumn 12, Issue 4, 2011, Pages 939-946

  Khokher, Samina ^a   Mahmood, Saqib ^b   Qureshi, Muhammad Usman ^b   Khan, Saeed Akhtar ^b   Chaudhry, Naseer Ahmad ^b  

^a INMOL Hospital   (Pakistan)

^b UNIVERSITY OF HEALTH SCIENCES   (Pakistan)

Author keywords

Advanced breast cancer; In vivo test; Initial clinical response; Neoadjuvant chemotherapy

Indexed keywords

EID: 84856289604     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: None     Document Type: Article

References (61)

1. Alexander W (2009). Meeting highlights: American Society of Clinical Oncology, 45th Annual Meeting. PandT, 34, 379-82.
2. Altman DG, Bland JM (1994). Diagnostic tests 1: sensitivity and specificity. BMJ, 308, 1552.
3. Altman DG, Bland JM (1994). Diagnostic tests 2:Predictive values. BMJ, 309, 102
4. Ardavanis A, Scorilas A, Tryfonopoulas D, et al (2006). Multidisciplinary therapy of locally Far-advanced or inflammatory breast cancer with fixed perioperative sequence of epirubicin, vinorelbine, and fluorouracil chemotherapy, surgery, and radiotherapy: long term results. The Oncologist, 11, 563-73.
5. Asakawa H, Koizumi H, Koike M, et al (2010). Prediction of breast cancer sensitivity to neoadjuvant chemotherapy based on status of DNA damage repair proteins. Breast Cancer Res, 12, 17.
6. Assfalg M, Bertini I, Colangiuli D, et al (2008). Evidence of different metabolic phenotypes in humans. PNAS, 105, 1420-4.
7. Aziz Z, Iqbal J, Akram M (2008). Effect of Social Class Disparities on disease stage, quality of treatment and survival outcomes in Breast Cancer patients from developing countries. Breast, 14, 372-5.
8. Aziz Z, Sara S, Akram M, et al (2004). Socioeconomic status and Breast Cancer Survival in Pakistani Women. J Pak Med Assoc, 54, 448-53.
9. Aziz Z (2008). Across Generations: Cancer Treatment in Developing Countries. J Clin Oncol, 26, 4990-1.
10. Beresford MJ, Stott D, Makris A (2008). Assessment of clinical response after two cycles of primary chemotherapy in breast cancer. Breast Cancer Res Treat, 109, 337-42.
11. Beslija S, Bonneterre J, Burstein HJ, et al (2009). Third consensus on medical treatment of metastatic breast cancer. Ann Oncol, 20, 1771-85.
12. Bhurgri Y, Bhurgri A, Nishter S, et al (2006). Pakistan - Country Profile of Cancer and Cancer Control 1995-2004. J Pak Med Asso, 56, 124-30.
13. Caraco Y (2004). Genes and the response to drugs. N Engl J Med, 351, 2867-9.
14. Cianfrocca MO, Gradishar W (2009). New molecular classifications of breast cancer. CA Cancer J Clin, 59, 303-13.
15. Deo AVS (2010). Challenges in the treatment of breast cancer in developing countries. Natl J Med India, 23, 129-31.
16. Doyle JJ, Neugut AI, Jacobson JS, et al (2005). Chemotherapy and Cardiotoxicity in Older Breast Cancer Patients: A Population-Based Study. J Clin Oncol, 23, 8597-8605.
17. Dowsett M, Dunbier AK (2008). Emerging biomarkers and new understanding of traditional markers in personalized therapy for breast cancer. Clin Cancer Res, 14, 8019-26.
18. EBCTCG (2005). Early breast cancer trialists collaborative group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15 years survival; an overview of randomized trials. Lancet, 365, 1687-1717.
19. El- Saghir NS, Eniu A, Carlson RW, et al (2008). Locally Advanced Breast Cancer treatment guideline implementation with particular attention to low and middle income countries. Cancer, 113, 2315-24.
20. Esteva FJ, Hortobagyi GN (2008). Can early response assessment guide neoadjuvant chemotherapy in early-stage breast cancer. JNCI, 100, 521-3.
21. FarmerP, Frenk J, Knaul FM, et al (2010). Expansion of cancer care and control in countries of low and middle income: a call for action. Lancet, 376, 1186-93.
22. Fiorentino C, Berruti A, Bottini A, et al (2001). Accuracy of mammography and echography versus clinical palpation in the assessment of response to primary chemotherapy in breast cancer patients with operable disease. Breast Cancer Res Treat, 69, 143-51.
23. Gilani GM, Kamal S, Akhter AS (2003). A Differential Study of Breast Cancer Patients in Punjab, Pakistan. J Pak Med Assoc, 53, 478-80.
24. Goldhirsch A, IngleJN, Gelber RD, et al (2009). Threshholds for therapies: Highlights of the st.Gallen International expert consensus on the primary therapy of early breast cancer. Ann Oncol, 20, 1319-29.
25. Graeser M, McCarthy A, Lord CJ, et al (2010). A marker of homologous recombination predicts pathologic complete response to neoadjuvant chemotherapy in primary breast cancer. Clin Cancer Res, 16, 6159-68.
26. Hayward JL, Carbone PP, Heuson JC, et al (1977). Assessment of response to therapy in advanced breast cancer; a project of the programme on clinical oncology of the international union against cancer, Geneva, Switzerland. Cancer, 39, 1289-94.
27. Herrada J, Iyer RB, Atkinson EN, et al (1997). Relative value of physical examination, mammography, and breast sonography in evaluating the size of the primary tumor and regional lymph node metastases in women receiving neoadjuvant chemotherapy for locally advanced breast carcinoma. Clin Cancer Res, 3, 1565-9.
28. Ishitobi M, Komoike Y, Motomura K, et al (2010). Early response to neo-adjuvant chemotherapy in carcinoma of the breast predicts both successful breast-conserving surgery and decreased risk of ipsilateral breast tumor recurrence. The Breast Journal, 16, 9-13.
29. Khokher S, Mahmood S, Khan SA (2010). Response to Neoadjuvant chemotherapy in patients with advanced breast cancer: A local hospital experience. Asian Pac J Cancer Prev, 11, 303-8.
30. Kuerer HM, Hunt KK, Newman LA, et al (2000). Neoadjuvant Chemotherapy in Women with Invasive Breast Carcinoma: Conceptual Basis and Fundamental Surgical Issues. J Am Coll Surg, 190, 350-63.
31. Labianca R, Gariassino M, Torri V (2008). Predicting response of molecularly targeted therapies: a still possible challenge? Ann Oncol, 19, 829-30.
32. Lancet (2009). Breast cancer in the developing countries. Lancet, 374, 1567
33. Mauri D, Pavlidis N, and Ioannidis JPA (2005). Neoadjuvant versus adjuvant systemic treatment in breast cancer: a metaanalysis. J Natl Cancer Inst, 97, 188-94.
34. McDermott U, Downing JR, Statton MR (2011). Genomics and the continuum of cancer care. N engl J Med, 364, 340-50.
35. Meisamy S, Bolan PJ, Baker EH, et al (2004). Neoadjuvant chemotherapy of locally advanced breast cancer: Pridicting Response with in vivo 1H MR spectroscopy-A pilot study at 4 T1. Radiology, 233, 424-31.
36. Miller AB, Hoogstraten B, Staquet M, et al (1981). Reporting results of cancer treatment. Cancer, 47, 207-14.
37. Moon YW, Rha SY, Jeung HC, et al (2005). Neoadjuvant chemotherapy with infusional 5-fluorouracil, adriamycin and cyclophosphamide (iFAC) in locally advanced breast cancer: an early response predicts good prognosis. Ann Oncol, 16, 1778-85.
38. National Breast Cancer Centre. Clinical practice guidelines for the management of advanced breast cancer. Canberra: Commonwealth of Australia:2001
39. NCCN (2011). National Comprehensive Cancer Network. NCCN Practice Guidelines in Oncology. Breast. Version 2. http://www.nccn.org/professionals/physician_gls/pdf/breast.pdf accessed on 18 january 2011.
40. Osako T, Horji R, Matsuura M, et al (2010). Common and discriminative clinicopathological features between breast cancers with pathological complete response or progressive disease in response to neoadjuvant chematheraoy. J Cancer Res Clin Oncol, 136, 233-241.
41. Park JS, Moon WK, Lyou CY, et al (2011). The assessment of breast cancer response to neoadjuvant chemotherapy: comparison of magnetic resonance imaging and18Ffluorodeoxyglucose positron emission tomography. Acta Radiologica, 52, 21-8
42. Parkin DM, Bray F, Ferlay J, et al (2005). Global Cancer Statistics 2002. CA. Cancer J Clin, 55, 74-108.
43. Padhani AR, Hayes C, Assersohn L, et al (2006). Prediction of clinicopathologic response of breast cancer to primary chemotherapy at contrast-enhanced MR imaging: initial clinical results. Radiology, 239, 361-74.
44. Peppercorn JM, Smith TJ, Helft PR, et al (2011). American Society of clinical oncology statement: Toward individualized care for patients with advanced cancer. J Clin Oncol DOI:10.1200/JCO.2010.33.1744.
45. Rakha EA, Reis-Filho JS, and Ellis IO (2010). Combinatorial biomarker expression in breast cancer. Breast Cancer Res Treat, 120, 293-308.
46. Raut NV and Chordiya N (2010). Neo adjuvant chemotherapy in breast cancer: What have we learned so far? Indian J Med Paediatr Oncol, 31, 8-17.
47. Rousseau C, Devillers A, Sagan C, et al (2006). Monitoring of early response to neoadjuvant chemotherapy in stage II and II breast cancer by [18F]Fluorodeoxyglucose Positron Emission Tomography. J Clin Oncol, 24, 5366-72.
48. Pruthi S, Boughey JC, Brandt KR, et al (2007). A Multidisciplinary Approach to the Management of Breast Cancer, Part 2; Therapeutic Considerations, Mayo Clin Proc. 82, 1131-40.
49. Rustogi A, Budrukkar A, Dinshaw K, et al (2005). Management of locally advanced breast cancer: evolution and current practice. J Cancer Res Ther, 1, 21-30.
50. Sharma S, Hiran KR, Pavithran K, et al (2009). A pilot study to assess the feasibility of evaluation of markers of response to chemotherapy at one day and 21days after first cycle of chemotherapy in carcinoma of breast: a prospective nonrandomized observational study. World Journal of Surgical Oncology. 7:35 doi:10.1186/1477-7819-7-35.
51. Schwarz JD, Bader M, Jenicke L, et al (2005). Early prediction of response to chemotherapy in metastatic breast cancer using sequential 18F-FDG PET. J Nucl Med, 46, 1144-50.
52. Shin HJ, Kim HH, Ahn JH, et al (2010). Comparison of mammography, sonography, MRI and clinical examination in patients with locally advanced or inflammatory breast cancer who underwent neoadjuvant chemotherapy. The British Journal of Radiology. doi:10.1259/bjr/74430952.
53. Sjoblom T, Jones S, Wood LD, et al (2006). The consensus coding sequences of human breast and colorectal cancers. Science, 314, 268-74.
54. Smith IC, Heys SD, Hutcheon AW, et al (2002). Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol, 20, 1456-66.
55. Sperber F, Weinstein Y, Sarid D, et al (2006). Preoperative clinical, mammographic and sonographic assessment of neoadjuvant chemotherapy response in breast cancer. IMAJ, 8, 342-6.
56. Tan SH, Lee SC, Goh BC, et al (2008). Pharmacogenetics in breast cancer therapy. Clin Cancer Res, 14, 8027-41.
57. Von Minckwitz G, Blohmer JU, Raab G, et al (2005). In vivo chemosensitivity-adapted preoperative chemotherapy in patients with early-stage breast cancer: the GEPARTRIO pilot study. Ann Oncol, 16, 56-63.
58. Von Minckwitz G, Kummel S, Vogel P, et al (2008). Intensified neoadjuvant chemotherapy in early-responding breast cancer: Phase III randomized GaperTrio Study. JNCI, 100, 552-62.
59. Von Minckwitz G, Sinn HP, Raab G, et al (2008). Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast.Breast Cancer Res.10:R30 doi:10.1186/bcr1989.
60. WHO Screening for breast cancer. [Online] (2008). Available from: http://www.who.int/cancer/detection/breastcancer/en/. Accessed on 25-11-2010.
61. Yu HJ, Chen JH, Mehta RS, et al (2007). MRI measurements of tumor size and pharmacokinetic parameters as early predictors of response in breast cancer patients undergoing neoadjuvant anthracycline chemotherapy. Journal of Magnetic Resonance Imaging, 26, 615-23.